Related Experiment Videos
[Next generation selective estrogen receptor modulators]
1Section of Gynecology, Yokohama City University Medical Center.
Clinical Calcium
|January 7, 2006
Summary
Novel selective estrogen receptor modulators (SERMs), lasofoxifene and bazedoxifene, show promise for osteoporosis prevention. These SERMs maintain bone health without adverse effects on uterine tissue or cholesterol levels.
Area of Science:
- Endocrinology
- Pharmacology
- Bone Biology
Context:
- Osteoporosis is a significant health concern for postmenopausal women.
- Estrogen replacement therapy offers skeletal benefits but carries risks.
- Selective estrogen receptor modulators (SERMs) aim to provide estrogen's benefits with reduced risks.
Purpose:
- To evaluate the efficacy of novel SERMs, lasofoxifene (LAS) and bazedoxifene (BZA), in preventing bone loss.
- To assess the tissue-selective effects of LAS and BZA on bone, uterus, and cholesterol levels.
Summary:
- Novel SERMs, LAS and BZA, demonstrated inhibition of bone turnover and prevention of bone loss in models of estrogen deficiency.
- These agents did not increase uterine endometrial thickness, unlike traditional hormone therapies.
- LAS and BZA also reduced serum cholesterol levels, suggesting cardiovascular benefits.
Impact:
- LAS and BZA represent promising therapeutic options for osteoporosis prevention in postmenopausal women.
- These SERMs offer a potential alternative to traditional hormone replacement therapy with an improved safety profile.
- Further research may validate these novel SERMs for widespread clinical use in managing menopausal bone health.